drugset / Trial / NCT05263869
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2 positive breast cancer with liver metastases.
Timeline
- Start
- 2022-03-23
- Primary completion
- 2022-12
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB VEDOTIN | Unknown | 2.6 mg/kg | Intravenous |